Susan Wysocki, WHNP-BC, FAANP
National Association of Nurse Practitioners in Womenís Health
THIS PROGRAM WAS ORIGINALLY PRESENTED AS AN AANP LIVE GROUP LECTURE SERIES (GLS) BEGINNING OCTOBER 23, 2009. IF YOU RECEIVED CREDIT FOR PARTICIPATING IN ONE OF THE LIVE GLS ACTIVITY, YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ONLINE ACTIVITY.
Female sexual dysfunction (FSD) is a common disorder affecting over 40 percent of women between the ages of 18-65. FSD may be attributable to a variety of causes. The most common form of FSD is hypoactive sexual desire disorder (HSDD). Women with HSDD experience emotional and psychological distress and significantly diminished sexual and partner relationship satisfaction. However, only one third of women with HSDD seek advice from a healthcare professional.
Targeted interviews and surveys with nurse practitioners (NPs) and other clinicians highlight the need to educate primary care and womenís health providers regarding normal sexual activity vs sexual dysfunction in their female patients. Nurse practitioners also report being challenged by the need to comfortably initiate conversations about sexual function with their female patients. Furthermore, NPs appear to lack the competency to diagnose HSDD, evaluate the causes of patientsí HSDD, and/or explain the factors that may contribute to HSDD. This program provides resources and tools for the diagnosis of HSDD, and utilizes video cases to exemplify how to discuss HSDD with patients.
Developed by the American Association of Nurse Practitioners in cooperation with
MCM Education Target Audience
This program was developed for nurse practitioners.
Upon completion of this educational activity, the participant should be able to:
Summarize the prevalence and definition of HSDD.
List the various causes that may contribute to sexual dysfunction and in particular HSDD.
Confidently initiate conversation on the topic of sexual dysfunction with patients.
Utilize tools and ask appropriate questions to help identify and distinguish HSDD.
Ms. Wysocki disclose her involvement on advisory boards for Ortho Womenís Health & Urology, Bayer HealthCare, Qiagen, Duramed, Eli Lilly, Wyeth, Merck, Upsher-Smith, Endo, Pharmaderm, and Boeringher; and participation on speakerís bureau for Bayer HealthCare, Duramed, Organon, Wyeth, Ther-rx, and Upsher-Smith.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. Credit Statements
This program is approved for 1.0 contact hour of continuing education (which includes 0.25 hours of pharmacology) by the American Academy of Nurse Practitioners. Program ID: 1004135.
This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.
Commercial Support Statements
This activity is supported through an educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc. Instructions
COMPLETING THE POST TEST AND EVALUATION:
When you return to the AANP CE Center, login and find the program you wish to complete. On the programís content page you can go directly to Start Post-Test at the bottom of the page. When you have successfully completed the online post-test you will be instructed to complete the online evaluation and then receive your certificate.
If you do not have a registration (email and password) with AANP, you will be asked to register: MyAANP. Complete the short profile and create your password to continue in the CE Center. Please contact Stormy Causey, CE Coordinator, at CECenter@aanp.org with any questions.
The opinions expressed in this presentation are those of the speaker and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the American Academy of Nurse Practitioners, or Boehringer Ingelheim Pharmaceuticals, Inc.